A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia

Molecular Psychiatry

Volumn 5, Issue 4, 2000, Pages 410-417

  Basile, V S ^a,f   Ozdemir V ^b   Masellis, M ^c   Walker, M L ^d   Meltzer, H Y ^d   Lieberman, J A ^e   Potkin, S G ^f   Alva, G ^a   Kalow, W ^b   Macciardp, F M ^c   Kennedy, J L ^a,f  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c VANDERBILT UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Antipsychotics; CYP1A2; Drug metabolism; Genetic association; Genetic polymorphism; Tardive dyskinesia

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SMOKING; TARDIVE DYSKINESIA;

EID: 0033939932     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000736     Document Type: Article

References (70)

1. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982; 39: 473-481.
2. Chakos MH, Alvir JM, Woerner MG, Koreen A, Geisler S, Mayerhoff D et al. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. Arch Gen Psychiatry 1996; S3: 313-319.
3. Bergen J, Kitchin R, Berry G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics. Biol Psychiatry 1992; 32: 580-594.
4. Peck CG, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 1992; 51: 465-473.
5. Rowland M, Tozer TN (eds). Clinical Pharmacokinetics. Concepts and Applications. 3rd edition. Williams & Wilkins: Pennsylvania, 1995.
6. Ozdemir V, Masellis M, Basile VS, Kalow W, Meltzer HY, Lieberman JA et al. Variability in response to clozapine: potential role of cytochrome P450 1A2 and the dopamine D4 receptor gene. CNS Spectrums 1999; 4: 30-56.
7. Weinhold P, Wegner JT, Kane JM. Familial occurrence of tardive dyskinesia. J Clin Psychiatry 1981; 42: 165-166.
8. Yassa R, Ananth J. Familial tardive dyskinesia. Am J Psychiatry 1981; 138: 1618-1619.
9. Waddington JL, Youssef HA. The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree. Br J Psychiatry 1988; 153: 376-381.
10. O'Callaghan E, Larkin G, Kinsella A, Waddington JL. Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia. Br J Psychiatry 1990; 157: 578-584.
11. Rosengarten H, Schweitzer JW, Friedhoff AJ. Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 1994; 49: 663-667.
12. Steen VM, Lovlie R, MacEwan T, McCreadie RG. Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol Psychiatry 1997; 2: 139-145.
13. Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, Lieberman JA et al. Association of the Mscl polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia. Neuropsychopharmacology 1999; 21: 17-27.
14. Segman R, Neeman T, Heresco-Levy U, Finkel B, Karagichev L, Schlafman M et al. Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 1999; 4: 247-253.
15. Bertilsson L, Dahl ML, Ekqvist B, Llerena A. Disposition of the neuroleptics perphenazine, zuclopenthixol, and haloperidol cosegregates with polymorphic debrisoquine hydroxylation. Psychopharmacol Ser 1993; 10: 230-237.
16. Bertilsson L, Dahl M-L. Polymorphic drug oxidation. Relevance to the treatment of psychiatric disorders. CAPS Drugs 1996; 5: 200-223.
17. Ozdemir V, Naranjo CA, Herrmann N, Reed K, Sellers EM, Kalow W. Paroxetine potentiates the central nervous system side-effects of perphenazine: contribution of cytochrome P450 2DG inhibition in vivo. Clin Pharmacol Ther 1997; 62: 334-347.
18. Kalow W. Pharmacogenetics in biological perspective. Pharmacol Rev 1997; 49: 369-379.
19. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sei 1391; 12: 102-107.
20. Bortilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (GYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.
21. Lin K-M, Poland RE, Wan Y-JY, Smith MW, Lesser IM. The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol Bull 1996; 32: 205-217.
22. Spina E, Sturiale V, Valvo S, Ancione M, Di Rosa AE, Meduri M et al. Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions. Ada Psychiatr Scand 1992; 86: 364-366.
23. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J din Psychopharmacol 1995; 15: 211-216.
24. Pollock BG, Mulsant BH, Sweet RA, Rosen J, Allied LP, Perel JM. Prospective cytochrome 450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31: 327-331.
25. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neurolepticinduced movement disorders in schizophrenic patients. Psychopharmacology 1997; 131: 174-179.
26. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2DG genotype. Br J Psychiatry 1997; 170: 23-26.
27. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32: 101-106.
28. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2DG) genotype in Japanese schizophrenics. Schizophr Res 1998; 32: 107-113.
29. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
30. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. EUT J Clin Pharmacol 1989; 36: 537-547.
31. Sindrup SH, Brosen K, Gram LF, Hailas J, Skjelbo E, Allen A et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 278-287.
32. Jerling M, Dahl ML, Aberg-Wistedt A, Liljenberg B, Landell NE, Bertilsson L et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59: 423-428.
33. Linnet K, Wiborg O. Steady-state serum concentrations of the neur-oleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther 1996; 60: 41-17.
34. Ozdemir V, Tyndale RF, Reed K, Herrmann N, Sellers EM, Kalow W et al. Paroxetine steady-state concentration in relation to CYP2DG genotype in extensive metabolizers. J Clin Psychopharmacol 1999; 19: 472-475.
35. Dahl-Puustinen ML, Liden A, Aim C, Nordin C, Bertilsson L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther 1989; 46: 78-81.
36. Pantuck EJ, Pantuck CB, Anderson KE, Conney AH, Kappas A. Cigarette smoking and chlorpromazino disposition and actions. Clin Pharmacol Ther 1982; 31: 533-538.
37. Stimmel GL, Falloon IR. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. J Clin Psychiatry 1983; 44: 420-422.
38. Ereshefsky L, Jann MW, Saklad SR, Davis CM, Richards AL, Burch NR. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985; 20: 329-332.
39. Jann MW, Saklad SR, Ereshefsky L, Richards AL, Harrington CA, Davis CM. Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance. Psychopharmacology (Berl) 1980; 00: 468-470.
40. Miller DD, Kelly MW, Perry PJ, Coryell WH. The influence of cigarette smoking on haloperidol pharmacokinetics. Biol Psychiatry 1990; 28: 529-531.
41. Shimoda K, Someya T, Morita S, Hirokane G, Noguchi T, Yokono A et al. Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients. Ther Drug Monit 1999; 21: 293-296.
42. Kalow W, Tang BK. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49: 44-48.
43. Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. Am J Psychiatry 1986; 143: 993-997.
44. Lohr JB, Flynn K. Smoking and schizophrenia. SchizophrRes 1992; 8: 93-102.
45. Smith SS, Fiore MC. The epidemiology of tobacco use, dependence, and cessation in the United States. Prim Core 1999; 26: 433-461.
46. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 (suppl 1): 1-21.
47. Kashuba AD, Nafziger AN, Kearns GL, Leeder JS, Gotschall R, Rocci ML Jr et al. Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clin Pharmacol Ther 1998; 64: 257-268.
48. Ozdemir V, Naranjo CA, Shulman RW, Herrmann N, Sellers EM, Kalow W et al. Determinants of interindividual variability and extent of CYP2DG and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo. J Clin Psychopharmacol 1998; 18: 198-207.
49. Rasmussen BB, Nielsen TL, Brosen K. Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. Pharmacol Toxicol 1998; 83: 240-245.
50. Daniel DG, Randolph C, Jaskiw G, Handel S, Williams T, AbiDargham A et al. Coadministration of fluvoxamine increases serum concentrations of haloperidol. J Clin Psychopharmacol 1994; 14: 340-343.
51. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM et al. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. Psychopharmacology 1996; 128: 398-407.
52. von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995; 15: 125-131.
53. Miller M, Opheim KE, Raisys VA, Motulsky AG. Theophylline metabolism: variation and genetics. Clin Pharmacol Ther 1984; 35: 170-182.
54. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508-519.
55. Kalow W, Tang DK, Endrenyi L. Hypothesis: comparisons of interand intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8: 283-289.
56. Sachse C, Brockmoller J, Bauer S, Roots I. Functional significance of C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999; 47: 445-449.
57. Lahiri DK, Nurnberger JI Jr. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
58. Kalow W. Pharmacogenetics: Heredity and the Response to Drugs. WB Saunders: Philadelphia, 1962.
59. Vesell ES. Reflections from distant cuvettes. Drug Metab Rev 1996; 28: 493-511.
60. Weber WW. Pharmacogenetics. Oxford University Press: New York, 1997.
61. Kalow W, Ozdemir V, Tang BK, Tothfalusi L, Endrenyi L. The science of pharmacological variability: an essay. Clin Pharmacol Ther 1999; GO: 445-447.
62. Okey AB. Enzyme induction in the cytochrome P-450 system. Pharmacol Thcr 1990; 45: 241-298.
63. Albers LJ, Reist C, Helmeste D, Vu R, Tang SW. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996; 59: 189-196.
64. Kalow W. Pharmacogenetic research: a revolutionary science. J Psychiatry Neurosci 1999; 24: 139-140.
65. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999; 125: 803-808.
66. Tang BK, Kalow W. Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans. Meth Enzymol 1996; 272: 124-131.
67. Kirch DG, Alho AM, Wyatt RJ. Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia. Cell Mol Neurobiol 1988; 8: 285-291.
68. Nilsson A, Waller L, Rosengren A, Adlerberth A, Wilhelmsen L. Cigarette smoking is associated with abnormal involuntary movements in the general male population-a study of men born in 1933. Biol Psychiatry 1097; 41: 717-723.
69. Dasile VS, Ozdemir V, Masellis M, Walker M, Kalow W, Meltzer HY et al. Tardive dyskinesia in schizophrenia: potential role and interaction of the cytochrome P450 1A2 and dopaminc D3 receptor genes. Am J Hum Genet 1999; G5: 242.
70. Macciardi FM, Basile VS, Kennedy JL. Modelling gene-gene interactions in complex traits. Am J Hum Genet 1999; 05: 210.